| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg | |||
| Other Sizes |
| Targets |
The two NHS ester groups react with primary amines (-NH2) on proteins, antibodies, or other amine-containing molecules to form stable amide bonds. The hydrophilic PEG spacer increases solubility in aqueous media. This enables crosslinking of two amine-containing molecules.
|
|---|---|
| ln Vitro |
Two distinct ligands, one for the E3 ubiquitin ligase and the other for the target protein, are present in PROTAC and are joined by a linker. PROTAC targets and selectively degrades target proteins by means of the intracellular ubiquitin-proteasome system. An ADC cytotoxin is connected to an antibody by use of an ADC linker to form an ADC.
In vitro activity is primarily related to its function as a PROTAC or ADC linker. Bis-PEG7-NHS ester enables the conjugation of two amine-containing molecules via amide bond formation. PROTACs synthesized using this linker facilitate targeted protein degradation. ADCs synthesized using this linker deliver cytotoxic payloads to target cells. |
| ln Vivo |
In vivo activity of Bis-PEG7-NHS ester is primarily inferred from its use in PROTAC and ADC development. PROTACs incorporating this linker can induce targeted protein degradation in vivo. ADCs synthesized using this linker deliver payloads to target cells. No direct in vivo activity data are specifically available for this linker alone.
|
| Enzyme Assay |
In vitro assays for Bis-PEG7-NHS ester typically involve evaluating crosslinking efficiency by reacting the NHS esters with primary amine-containing molecules at pH 7-9. Reaction efficiency is assessed by SDS-PAGE, mass spectrometry, or HPLC. Purity is assessed by HPLC. Solubility is evaluated in aqueous and organic solvents.
|
| Cell Assay |
Cell-based assays for Bis-PEG7-NHS ester are conducted in the context of PROTAC or ADC activity. Cells are treated with PROTACs or ADCs synthesized using this linker. Target protein degradation is assessed by Western blot or immunofluorescence. Cytotoxicity is measured by MTT or CellTiter-Glo assays. Antigen-specific cell killing is evaluated for ADCs.
|
| Animal Protocol |
In vivo animal studies for Bis-PEG7-NHS ester are conducted in the context of PROTAC or ADC efficacy. Tumor-bearing mice are treated with PROTACs or ADCs synthesized using this linker. Tumor growth inhibition is monitored. Target protein degradation in tissues is assessed by Western blot or immunohistochemistry. Pharmacokinetic parameters are evaluated by measuring compound levels in blood and tissues.
|
| ADME/Pharmacokinetics |
As a PEG-based linker, Bis-PEG7-NHS ester has favorable aqueous solubility due to the hydrophilic PEG spacer. The NHS esters are hydrolytically unstable and should be used fresh. No specific PK data are available for this linker alone; its PK profile is determined by the conjugated molecule.
|
| Toxicity/Toxicokinetics |
No detailed toxicology data are specifically available for Bis-PEG7-NHS ester. PEG-based compounds are generally considered to have low toxicity and good biocompatibility. The compound is for research use only and not intended for therapeutic use. Standard laboratory safety precautions should be followed. Store at -20°C.
|
| References | |
| Additional Infomation |
Bis-PEG7-NHS ester (CAS#: 1334170-02-3) is a PEG linker with two NHS ester groups. It is a PROTAC bridge and cleavable ADC linker. It is used for bioconjugation via NHS ester chemistry. It is for research use only and not an approved therapeutic agent.
|
| Molecular Formula |
C26H40N2O15
|
|---|---|
| Molecular Weight |
620.600209236145
|
| Exact Mass |
620.242
|
| CAS # |
1334170-02-3
|
| PubChem CID |
53486139
|
| Appearance |
Colorless to light yellow viscous liquid
|
| LogP |
-2.9
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
28
|
| Heavy Atom Count |
43
|
| Complexity |
798
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
QWDCSPQIVZTPRD-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C26H40N2O15/c29-21-1-2-22(30)27(21)42-25(33)5-7-35-9-11-37-13-15-39-17-19-41-20-18-40-16-14-38-12-10-36-8-6-26(34)43-28-23(31)3-4-24(28)32/h1-20H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 3-[2-[2-[2-[2-[2-[2-[3-(2,5-dioxopyrrolidin-1-yl)oxy-3-oxopropoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]propanoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~161.13 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (4.03 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6113 mL | 8.0567 mL | 16.1134 mL | |
| 5 mM | 0.3223 mL | 1.6113 mL | 3.2227 mL | |
| 10 mM | 0.1611 mL | 0.8057 mL | 1.6113 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
